Related Experiment Videos
Tedisamil: a new novel antiarrhythmic.
Bethan Freestone1, Gregory Y H Lip
1University Department of Medicine, City Hospital, Birmingham, UK.
Expert Opinion on Investigational Drugs
|March 5, 2004
Summary
Tedisamil, a novel antiarrhythmic, effectively treats angina by improving exercise capacity and reducing ischemic events. It also shows promise for atrial fibrillation treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Tedisamil (KC-8857) is a novel antiarrhythmic drug developed by Solvay Pharmaceuticals.
- It exhibits potassium channel blockade, classifying it as a Class III antiarrhythmic agent.
- The drug also possesses anti-ischemic properties.
Purpose of the Study:
- To evaluate tedisamil's efficacy and safety as an antianginal agent.
- To investigate tedisamil's potential for treating atrial fibrillation.
Main Methods:
- Phase I trials assessed tedisamil's bradycardic and QT interval effects.
- Phase II trials evaluated hemodynamic and anti-ischemic effects in ischemic heart disease patients.
- Phase III trials compared tedisamil to placebo in angina pectoris treatment.
Main Results:
- Tedisamil demonstrated beneficial hemodynamic and anti-ischemic effects in Phase II trials.
- Phase III trials showed tedisamil effectively treats angina, increasing anginal threshold and exercise capacity.
- A dose-dependent improvement in exercise-induced ischemia was observed.
Conclusions:
- Tedisamil is an effective anti-ischemic agent for angina pectoris.
- Further clinical trials (Phase II/III) are ongoing for atrial fibrillation treatment.